GlassScriptPhysician profile
Marjorie Cunningham
NPI 1295927861
$16,064.49
in general payments reported to CMS, 2019-2025
55 companies · $3,497 in 2025
The $3,497 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,842 · 2022: $3,180 · 2023: $3,415 · 2024: $3,131 · 2025: $3,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,647 · Education: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,647.10 |
| Education | $395.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,127.32 | 2021-2025 | Darzalex, Erleada, Tecvayli |
| Pfizer INC. | $1,868.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,227.16 | 2021-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals LP | $1,220.86 | 2021-2025 | Imfinzi, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $1,144.32 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $745.22 | 2021-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $582.39 | 2021-2025 | Enhertu, Datroway |
| Amgen INC. | $567.29 | 2021-2023 | Kyprolis, Vectibix, Xgeva |
| Seagen INC. | $454.55 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Lilly USA, LLC | $437.15 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $370.83 | 2022-2025 | |
| Beigene USA, INC. | $338.47 | 2021-2024 | Brukinsa |
| Eisai INC. | $305.12 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $300.28 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Abbvie INC. | $299.27 | 2021-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $285.34 | 2023-2025 | Orgovyx |
| Myovant Sciences INC. | $275.17 | 2021-2022 | |
| Emd Serono, INC. | $270.12 | 2021-2025 | Bavencio |
| Genzyme Corporation | $266.77 | 2022-2025 | |
| Incyte Corporation | $232.81 | 2021-2023 | Jakafi |
| Tolmar, INC. | $207.88 | 2023-2025 | Rubraca, Eligard |
| Coherus Oncology, INC. | $168.84 | 2021-2022 | |
| Stemline Therapeutics INC. | $148.82 | 2023-2025 | Orserdu |
| Tolmar Pharmaceuticals, INC. | $147.72 | 2021-2022 | |
| Epizyme, INC. | $146.83 | 2021-2022 | |
| Astellas Pharma US INC | $141.07 | 2021-2025 | Xtandi |
| Array Biopharma INC | $138.36 | 2021-2025 | Braftovi, Lorbrena, Mektovi |
| Mirati Therapeutics, INC. | $129.37 | 2023 | Krazati |
| Glaxosmithkline, LLC. | $125.65 | 2023-2025 | Zejula, Jemperli |
| Pharmacyclics LLC, An Abbvie Company | $110.39 | 2021-2022 | |
| Exelixis INC. | $108.77 | 2021-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $100.15 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $95.33 | 2022-2025 | Libtayo, Lynozyfic |
| Alexion Pharmaceuticals, INC. | $94.48 | 2025 | Ultomiris |
| Celgene Corporation | $93.94 | 2021-2022 | |
| Pharmaand Gmbh | $74.90 | 2025 | Rubraca |
| Ipsen Biopharmaceuticals, INC | $63.09 | 2024-2025 | Onivyde, Somatuline Depot |
| Geron Corporation | $60.86 | 2025 | Rytelo |
| Gilead Sciences, INC. | $59.93 | 2022-2023 | Trodelvy |
| Organon LLC | $50.75 | 2021-2022 | |
| Blueprint Medicines Corporation | $47.86 | 2025 | Ayvakit |
| Kyowa Kirin, INC. | $43.92 | 2021-2022 | |
| Puma Biotechnology, INC. | $42.58 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $39.81 | 2023 | Monoferric |
| Genmab U.S., INC. | $39.59 | 2023-2024 | Epkinly |
| Beone Medicines USA, INC. | $36.38 | 2025 | Tevimbra, Brukinsa |
| Dendreon Pharmaceuticals LLC | $34.44 | 2025 | Provenge |
| Sun Pharmaceutical Industries INC. | $31.96 | 2023-2024 | Yonsa, Odomzo |
| Janssen Pharmaceuticals, INC | $28.36 | 2021 | |
| Genentech USA, INC. | $24.23 | 2023 | Tecentriq |
| Morphosys, US INC. | $24.06 | 2023 | Monjuvi |
| Sobi, INC | $23.36 | 2023 | |
| Amneal Pharmaceuticals LLC | $22.75 | 2024 | Avastin, Neulasta, Neupogen |
| Deciphera Pharmaceuticals INC. | $21.38 | 2021 | |
| Taiho Oncology, INC. | $17.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.